Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma

ABSTRACT Background: Breast cancer (BC) is the most common malignancy in women. Aim: To assess the impact of HER2 status on axillary lymph node (ALN) involvement in patients with invasive ductal carcinoma of no special type (IDC-NST) both at diagnosis and during the 4-year postoperative period. P...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kustic,Domagoj, Lovasic,Franjo, Belac-Lovasic,Ingrid, Avirovic,Manuela, Ruzic,Alen, Petretic-Majnaric,Silvana
Lenguaje:	English
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Breast Neoplasms Receptor, ErbB-2 Sentinel Lymph Node Trastuzumab
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000500557
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872019000500557
record_format	dspace
spelling	oai:scielo:S0034-988720190005005572020-02-28Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinomaKustic,DomagojLovasic,FranjoBelac-Lovasic,IngridAvirovic,ManuelaRuzic,AlenPetretic-Majnaric,Silvana Breast Neoplasms Receptor, ErbB-2 Sentinel Lymph Node Trastuzumab ABSTRACT Background: Breast cancer (BC) is the most common malignancy in women. Aim: To assess the impact of HER2 status on axillary lymph node (ALN) involvement in patients with invasive ductal carcinoma of no special type (IDC-NST) both at diagnosis and during the 4-year postoperative period. Patients and Methods: We retrospectively included 375 women with an early clinical stage of non-luminal IDC-NST who between 2007 and 2013 underwent breast surgery at a clinical hospital. They were divided into phenotype-based groups: HR+HER2-, HR+HER2+, HR-HER2+ and HR-HER2-. Only patients with sentinel lymph node (SLN) macrometastases underwent ALN dissection. If > 3 ALNs were positive, radiotherapy was delivered. All patients were treated with chemotherapy, HER2+ BC patients received trastuzumab, and hormone receptor (HR)-positive BC patients received hormonal therapy. Results: Larger tumor size, higher grade, HR+, HER2+ status, and lymphovascular invasion (LVI) were predictive for ALN metastases at diagnosis. The poorest overall, disease-free, and distant recurrence-free survival (OS, DFS, DRFS) were found in the HR-HER2- group, while the poorest locoregional recurrence-free survival (LRFS) was observed in HR-HER2+ and HR-HER2- groups. HER2 status was not predictor of survival. Conclusions: HER2+ status was predictive for ALN involvement at diagnosis but had no effect on 4-year LRFS in these patients.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.5 20192019-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000500557en10.4067/S0034-98872019000500557
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Breast Neoplasms Receptor, ErbB-2 Sentinel Lymph Node Trastuzumab
spellingShingle	Breast Neoplasms Receptor, ErbB-2 Sentinel Lymph Node Trastuzumab Kustic,Domagoj Lovasic,Franjo Belac-Lovasic,Ingrid Avirovic,Manuela Ruzic,Alen Petretic-Majnaric,Silvana Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
description	ABSTRACT Background: Breast cancer (BC) is the most common malignancy in women. Aim: To assess the impact of HER2 status on axillary lymph node (ALN) involvement in patients with invasive ductal carcinoma of no special type (IDC-NST) both at diagnosis and during the 4-year postoperative period. Patients and Methods: We retrospectively included 375 women with an early clinical stage of non-luminal IDC-NST who between 2007 and 2013 underwent breast surgery at a clinical hospital. They were divided into phenotype-based groups: HR+HER2-, HR+HER2+, HR-HER2+ and HR-HER2-. Only patients with sentinel lymph node (SLN) macrometastases underwent ALN dissection. If > 3 ALNs were positive, radiotherapy was delivered. All patients were treated with chemotherapy, HER2+ BC patients received trastuzumab, and hormone receptor (HR)-positive BC patients received hormonal therapy. Results: Larger tumor size, higher grade, HR+, HER2+ status, and lymphovascular invasion (LVI) were predictive for ALN metastases at diagnosis. The poorest overall, disease-free, and distant recurrence-free survival (OS, DFS, DRFS) were found in the HR-HER2- group, while the poorest locoregional recurrence-free survival (LRFS) was observed in HR-HER2+ and HR-HER2- groups. HER2 status was not predictor of survival. Conclusions: HER2+ status was predictive for ALN involvement at diagnosis but had no effect on 4-year LRFS in these patients.
author	Kustic,Domagoj Lovasic,Franjo Belac-Lovasic,Ingrid Avirovic,Manuela Ruzic,Alen Petretic-Majnaric,Silvana
author_facet	Kustic,Domagoj Lovasic,Franjo Belac-Lovasic,Ingrid Avirovic,Manuela Ruzic,Alen Petretic-Majnaric,Silvana
author_sort	Kustic,Domagoj
title	Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
title_short	Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
title_full	Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
title_fullStr	Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
title_full_unstemmed	Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
title_sort	impact of her2 receptor status on axillary nodal burden in patients with non-luminal a invasive ductal breast carcinoma
publisher	Sociedad Médica de Santiago
publishDate	2019
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000500557
work_keys_str_mv	AT kusticdomagoj impactofher2receptorstatusonaxillarynodalburdeninpatientswithnonluminalainvasiveductalbreastcarcinoma AT lovasicfranjo impactofher2receptorstatusonaxillarynodalburdeninpatientswithnonluminalainvasiveductalbreastcarcinoma AT belaclovasicingrid impactofher2receptorstatusonaxillarynodalburdeninpatientswithnonluminalainvasiveductalbreastcarcinoma AT avirovicmanuela impactofher2receptorstatusonaxillarynodalburdeninpatientswithnonluminalainvasiveductalbreastcarcinoma AT ruzicalen impactofher2receptorstatusonaxillarynodalburdeninpatientswithnonluminalainvasiveductalbreastcarcinoma AT petreticmajnaricsilvana impactofher2receptorstatusonaxillarynodalburdeninpatientswithnonluminalainvasiveductalbreastcarcinoma
_version_	1718437061601525760

Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma

Ejemplares similares